Food Addiction and Follow-up in Subjects With Obesity

Obesity Clinical Trial

— ADDICTAL  

Official title:

Impact of Follow-up in Subjects With Obesity and Food Addiction

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04218097
• Other study ID #: 69HCL19_0401
• Status: Completed
• Start date: March 30, 2020
• Est. completion date: June 1, 2020

Study information

• Verified date: August 2022
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Obesity is a chronic disease. Its prevalence, which is constantly increasing, as well as the morbidity and mortality caused, require the development of new treatments, particularly for associated eating disorders. Indeed, it has been shown that a participation of abnormalities of food addiction type behaviour was frequently found in patients hospitalized for obesity (25% of patients). These disorders require specific management if you want to achieve a good weight result. The aim of the study is to compare the weight evolution of patients with addiction-type disorder (addict) versus those without addiction (non-addict) as well as the management modalities.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: June 1, 2020
• Est. primary completion date: June 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Obese patients grade 2 and 3
• Hospitalized in Endocrinology A from January 1, 2017 to January 1, 2018
• Over 18 years of age
• Not objecting to its participation

Exclusion Criteria:

• No understanding of French

Related Conditions & MeSH terms

• Behavior, Addictive
• Eating Disorders
• Feeding and Eating Disorders
• Food Addiction
• Obesity

Intervention

Other:
• Study questionnaire
Monitoring - data collection: Sending of an information form and the study questionnaire, the YFAS and Hospital Anxiety and Depression (HAD) scale by post within a follow-up period of 24 to 36 months. With a stamped envelope for the answer and a telephone reminder if necessary.

Locations

Country	Name	City	State
France	Service Endocrinologie, Hôpital Lyon Sud,	Pierre-Bénite

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Weight change: difference between the current weight reported in a questionnaire and the weight measured at the end of hospitalization	Evaluate the weight evolution of patients according to their addictive or non-addictive nature, 24-36 months after their discharge from hospital, in Endocrinology for initial obesity assessment.	month 36